Base de dados : MEDLINE
Pesquisa : N02.421.726.608 [Categoria DeCS]
Referências encontradas : 9069 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 907 ir para página                         

  1 / 9069 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457673
[Au] Autor:Lu PJ; O'Halloran A; Kennedy ED; Williams WW; Kim D; Fiebelkorn AP; Donahue S; Bridges CB
[Ad] Endereço:Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Atlanta, GA 30333, USA. Electronic address: lhp8@cdc.gov.
[Ti] Título:Awareness among adults of vaccine-preventable diseases and recommended vaccinations, United States, 2015.
[So] Source:Vaccine;35(23):3104-3115, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Adults are recommended to receive select vaccinations based on their age, underlying medical conditions, lifestyle, and other considerations. Factors associated with awareness of vaccine-preventable diseases and recommended vaccines among adults in the United States have not been explored. METHODS: Data from a 2015 internet panel survey of a nationally representative sample of U.S. adults aged ≥19years were analyzed to assess awareness of selected vaccine-preventable diseases and recommended vaccines for adults. A multivariable logistic regression model with a predictive marginal approach was used to identify factors independently associated with awareness of selected vaccine-preventable infections/diseases and corresponding vaccines. RESULTS: Among the surveyed population, from 24.6 to 72.1% reported vaccination for recommended vaccines. Awareness of vaccine-preventable diseases among adults aged ≥19years ranged from 63.4% to 94.0% (63.4% reported awareness of HPV, 71.5% reported awareness of tetanus, 72.0% reported awareness of pertussis, 75.4% reported awareness of HZ, 75.8% reported awareness of hepatitis B, 83.1% reported awareness of pneumonia, and 94.0% reported awareness of influenza). Awareness of the corresponding vaccines among adults aged ≥19years ranged from 59.3% to 94.1% (59.3% HZ vaccine, 59.6% HPV vaccine, 64.3% hepatitis B vaccine, 66.2% pneumococcal vaccine, 86.3% tetanus vaccines, and 94.1% influenza vaccine). In multivariable analysis, being female and being a college graduate were significantly associated with a higher level of awareness for majority of vaccine-preventable diseases, and being female, being a college graduate, and working as a health care provider were significantly associated with a higher level of awareness for majority of corresponding vaccines. CONCLUSIONS: Although adults in this survey reported high levels of awareness for most vaccines recommended for adults, self-reported vaccination coverage was not optimal. Combining interventions known to increase uptake of recommended vaccines, such as patient reminder/recall systems and other healthcare system-based interventions, and ensuring patients' vaccination needs are assessed, are needed to improve vaccination of adults.
[Mh] Termos MeSH primário: Controle de Doenças Transmissíveis/estatística & dados numéricos
Conhecimentos, Atitudes e Prática em Saúde
Programas de Imunização
Vacinação/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adulto
Idoso
Escolaridade
Feminino
Hepatite B/prevenção & controle
Vacinas contra Hepatite B/administração & dosagem
Seres Humanos
Vacinas contra Influenza/administração & dosagem
Modelos Logísticos
Masculino
Meia-Idade
Vacinas contra Papillomavirus/administração & dosagem
Vacinas Pneumocócicas/administração & dosagem
Fatores Sexuais
Tétano/prevenção & controle
Estados Unidos
Vacinação/psicologia
Coqueluche/prevenção & controle
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis B Vaccines); 0 (Influenza Vaccines); 0 (Papillomavirus Vaccines); 0 (Pneumococcal Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  2 / 9069 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28456529
[Au] Autor:Shankar MB; Staples JE; Meltzer MI; Fischer M
[Ad] Endereço:Division for Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C-18, Atlanta, GA 30329, USA. Electronic address: kiu8@cdc.gov.
[Ti] Título:Cost effectiveness of a targeted age-based West Nile virus vaccination program.
[So] Source:Vaccine;35(23):3143-3151, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: West Nile virus (WNV) is the leading cause of domestically-acquired arboviral disease in the United States. Several WNV vaccines are in various stages of development. We estimate the cost-effectiveness of WNV vaccination programs targeting groups at increased risk for severe WNV disease. METHODS: We used a mathematical model to estimate costs and health outcomes of vaccination with WNV vaccine compared to no vaccination among seven cohorts, spaced at 10year intervals from ages 10 to 70years, each followed until 90-years-old. U.S. surveillance data were used to estimate WNV neuroinvasive disease incidence. Data for WNV seroprevalence, acute and long-term care costs of WNV disease patients, quality-adjusted life-years (QALYs), and vaccine characteristics were obtained from published reports. We assumed vaccine efficacy to either last lifelong or for 10years with booster doses given every 10years. RESULTS: There was a statistically significant difference in cost-effectiveness ratios across cohorts in both models and all outcomes assessed (Kruskal-Wallis test p<0.0001). The 60-year-cohort had a mean cost per neuroinvasive disease case prevented of $664,000 and disability averted of $1,421,000 in lifelong model and $882,000 and $1,887,000, respectively in 10-year immunity model; these costs were statistically significantly lower than costs for other cohorts (p<0.0001). Vaccinating 70-year-olds had the lowest cost per death averted in both models at around $4.7 million (95%CI $2-$8 million). Cost per disease case averted was lowest among 40- and 50-year-old cohorts and cost per QALY saved lowest among 60-year cohorts in lifelong immunity model. The models were most sensitive to disease incidence, vaccine cost, and proportion of persons developing disease among infected. CONCLUSIONS: Age-based WNV vaccination program targeting those at higher risk for severe disease is more cost-effective than universal vaccination. Annual variation in WNV disease incidence, QALY weights, and vaccine costs impact the cost effectiveness ratios.
[Mh] Termos MeSH primário: Programas de Imunização/economia
Vacinas contra o Vírus do Nilo Ocidental/economia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Criança
Análise Custo-Benefício
Feminino
Seres Humanos
Imunização Secundária/economia
Masculino
Cadeias de Markov
Meia-Idade
Método de Monte Carlo
Anos de Vida Ajustados por Qualidade de Vida
Fatores de Risco
Estudos Soroepidemiológicos
Estados Unidos/epidemiologia
Vacinação/economia
Febre do Nilo Ocidental/epidemiologia
Febre do Nilo Ocidental/prevenção & controle
Vacinas contra o Vírus do Nilo Ocidental/administração & dosagem
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (West Nile Virus Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE


  3 / 9069 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28456526
[Au] Autor:Adjagba A; MacDonald NE; Ortega-Pérez I; Duclos P; 2016 Global NITAG Network Meeting Participants
[Ad] Endereço:Health Policy and Institutional Development (HPID) Center, Agence de Médecine Préventive, Paris, France.
[Ti] Título:Strengthening and sustainability of national immunization technical advisory groups (NITAGs) globally: Lessons and recommendations from the founding meeting of the global NITAG network.
[So] Source:Vaccine;35(23):3007-3011, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:National Immunization Technical Advisory Groups (NITAGs) provide independent, evidence-informed advice to assist their governments in immunization policy formation. However, many NITAGs face challenges in fulfilling their roles. Hence the many requests for formation of a network linking NITAGs together so they can learn from each other. To address this request, the Health Policy and Institutional Development (HPID) Center (a WHO Collaborating Center at the Agence de Médecine Préventive - AMP), in collaboration with WHO, organized a meeting in Veyrier-du-Lac, France, on 11 and 12 May 2016, to establish a Global NITAG Network (GNN). The meeting focused on two areas: the requirements for (a) the establishment of a global NITAG collaborative network; and (b) the global assessment/evaluation of the performance of NITAGs. 35 participants from 26 countries reviewed the proposed GNN framework documents and NITAG performance evaluation. Participants recommended that a GNN should be established, agreed on its governance, function, scope and a proposed work plan as well as setting a framework for NITAG evaluation.
[Mh] Termos MeSH primário: Comitês Consultivos
Saúde Global
Política de Saúde
Programas de Imunização/organização & administração
[Mh] Termos MeSH secundário: Comitês Consultivos/legislação & jurisprudência
Comitês Consultivos/organização & administração
Comitês Consultivos/estatística & dados numéricos
Congressos como Assunto
França
Seres Humanos
Programas de Imunização/legislação & jurisprudência
Programas de Imunização/estatística & dados numéricos
Programas de Imunização/tendências
Colaboração Intersetorial
Vacinas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE


  4 / 9069 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Texto completo
[PMID]:28455173
[Au] Autor:Dombkowski KJ; Cowan AE; Reeves SL; Foley MR; Dempsey AF
[Ad] Endereço:The Child Health Evaluation and Research (CHEAR) Center, Division of General Pediatrics, University of Michigan, 300 N Ingalls St, Ann Arbor, MI 48109, United States. Electronic address: kjd@med.umich.edu.
[Ti] Título:The impacts of email reminder/recall on adolescent influenza vaccination.
[So] Source:Vaccine;35(23):3089-3095, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: We sought to: (1) explore the feasibility of using email for seasonal influenza vaccination reminders to parents of adolescents and (2) assess influenza vaccination rates among adolescents whose parents were randomized to either receive or not receive email reminders. METHODS: Email addresses were obtained for parents of patients 10-18years from 4 practices in Michigan. Addresses were randomized to either receive email reminders, or not. Reminder messages were sent during October 2012-March 2013 (Season 1) and October 2013-March 2014 (Season 2). Vaccination status was determined 60days following the last email reminder for each season using the statewide Michigan Care Improvement Registry (MCIR); per protocol bivariate and multivariate logistic regression analyses were conducted to evaluate reminder notification. RESULTS: After email cleaning, testing, and matching with MCIR, approximately half of email addresses (2348 of 5312 in Season 1; 3457 of 6549 in Season 2) were randomized. Bivariate analyses found that influenza vaccination within 60days after notification date was similar among those notified (34%) versus not notified (29%) in both Season 1 (p=0.06) and Season 2 (39% vs. 37%, p=0.20). However, multivariate models adjusted for season, site, and receipt of notification in two seasons found a higher likelihood of influenza vaccination among children that received notification (aOR=1.28, 95% CI=1.09, 1.51); in addition, differences in influenza vaccination were also observed between practice sites (range: p=0.15 to p<0.001). CONCLUSIONS: We found that practice-based email influenza vaccine reminders to parents of adolescents are feasible, but not without complications. Our study demonstrates that email reminders from practices can yield increases in influenza vaccination rates among adolescents. Practices should consider email as an option for influenza reminders and establish business practices for collecting and maintaining patient email addresses. This study is registered at www.ClinicalTrials.gov id #NCT01732315.
[Mh] Termos MeSH primário: Correio Eletrônico
Programas de Imunização/métodos
Vacinas contra Influenza
Influenza Humana/prevenção & controle
Sistema de Registros
Sistemas de Alerta/instrumentação
[Mh] Termos MeSH secundário: Adolescente
Criança
Feminino
Seres Humanos
Vacinas contra Influenza/administração & dosagem
Masculino
Michigan
Pais
Estações do Ano
Mensagem de Texto
Vacinação
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Influenza Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  5 / 9069 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449971
[Au] Autor:Tsaban G; Ben-Shimol S
[Ad] Endereço:Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer Sheva, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
[Ti] Título:Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: A systematic review of the literature.
[So] Source:Vaccine;35(22):2882-2891, 2017 05 19.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Pneumococcal diseases are major causes of morbidity among adults, especially those over 50years of age. While pneumococcal conjugated vaccines (PCV's) impact on pneumococcal disease rates among children is well established, the extent of its impact on adult pneumococcal related illness remains unclear. The aim of this systematic literature review was to describe the impact of PCV introduction to childhood national immunization programs worldwide on PCV-naive adult population. METHODS: A systematic literature search was performed using the PubMed database. The search was limited to articles written in English and published between January 2000 and February 2016. Studies evaluating pneumococcal disease rates in individuals over 5years of age were included. Independent extraction of articles was performed by the two authors. Search terms included: Pneumococcal conjugated vaccine, herd, indirect, adults, and pneumonia. RESULTS: Forty-nine articles meeting the selection criteria were identified, 39 regarding invasive pneumococcal disease (IPD, one on meningitis only), 8 regarding pneumonia, and 2 on both IPD and pneumonia. The majority of reports were from the US, UK and Canada. Considerable variability in the data sources, quality and completeness was observed. While most studies reported either statistically significant reduction or insignificant changes in IPD and pneumonia disease rates in adults following PCV nationwide implementation, few studies reported statistically significant increase in pneumococcal disease rates, these were mainly from countries with low PCV coverage rates and/or inadequate surveillance. CONCLUSION: Invasive pneumococcal diseases and pneumonia rates among the adult population decreased in most countries following PCV introduction into the NIP. This indirect effect on older population seems to be dependent on PCV coverage rates and time from PCV nationwide implementation. Adults >65years old seem to benefit the most from PCV introduction.
[Mh] Termos MeSH primário: Imunidade Coletiva
Programas de Imunização
Vacinas Pneumocócicas/imunologia
Pneumonia Pneumocócica/prevenção & controle
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Canadá/epidemiologia
Criança
Pré-Escolar
Feminino
Seres Humanos
Masculino
Meia-Idade
Infecções Pneumocócicas/epidemiologia
Infecções Pneumocócicas/imunologia
Infecções Pneumocócicas/prevenção & controle
Vacinas Pneumocócicas/administração & dosagem
Pneumonia Pneumocócica/epidemiologia
Pneumonia Pneumocócica/microbiologia
Streptococcus pneumoniae/imunologia
Vacinação
Vacinas Conjugadas/administração & dosagem
Vacinas Conjugadas/imunologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Pneumococcal Vaccines); 0 (Vaccines, Conjugate)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  6 / 9069 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29494568
[Au] Autor:Bolu O; Nnadi C; Damisa E; Braka F; Siddique A; Archer WR; Bammeke P; Banda R; Higgins J; Edukugo A; Nganda GW; Forbi JC; Liu H; Gidado S; Soghaier M; Franka R; Waziri N; Burns CC; Vertefeuille J; Wiesen E; Adamu U
[Ti] Título:Progress Toward Poliomyelitis Eradication - Nigeria, January-December 2017.
[So] Source:MMWR Morb Mortal Wkly Rep;67(8):253-256, 2018 Mar 02.
[Is] ISSN:1545-861X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Nearly three decades after the World Health Assembly launched the Global Polio Eradication Initiative in 1988, four of the six World Health Organization (WHO) regions have been certified polio-free (1). Nigeria is one of three countries, including Pakistan and Afghanistan, where wild poliovirus (WPV) transmission has never been interrupted. In September 2015, after >1 year without any reported WPV cases, Nigeria was removed from WHO's list of countries with endemic WPV transmission (2); however, during August and September 2016, four type 1 WPV (WPV1) cases were reported from Borno State, a state in northeastern Nigeria experiencing a violent insurgency (3). The Nigerian government, in collaboration with partners, launched a large-scale coordinated response to the outbreak (3). This report describes progress in polio eradication activities in Nigeria during January-December 2017 and updates previous reports (3-5). No WPV cases have been reported in Nigeria since September 2016; the latest case had onset of paralysis on August 21, 2016 (3). However, polio surveillance has not been feasible in insurgent-controlled areas of Borno State. Implementation of new strategies has helped mitigate the challenges of reaching and vaccinating children living in security-compromised areas, and other strategies are planned. Despite these initiatives, however, approximately 130,000-210,000 (28%-45%) of the estimated 469,000 eligible children living in inaccessible areas in 2016 have not been vaccinated. Sustained efforts to optimize surveillance and improve immunization coverage, especially among children in inaccessible areas, are needed.
[Mh] Termos MeSH primário: Erradicação de Doenças
Poliomielite/prevenção & controle
Vacinas contra Poliovirus/administração & dosagem
Vigilância da População
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Seres Humanos
Programas de Imunização
Lactente
Nigéria/epidemiologia
Poliomielite/epidemiologia
Poliovirus/isolamento & purificação
Vacinas contra Poliovirus/efeitos adversos
Medidas de Segurança
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Poliovirus Vaccines)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180302
[St] Status:MEDLINE
[do] DOI:10.15585/mmwr.mm6708a5


  7 / 9069 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29498497
[Ti] Título:Progress towards poliomyelitis eradication: Nigeria, January­December 2017.
[Ti] Título:Progrès vers l'éradication de la poliomyélite au Nigéria, janvier-décembre 2017..
[So] Source:Wkly Epidemiol Rec;93(9):97-104, 2018 Mar 02.
[Is] ISSN:0049-8114
[Cp] País de publicação:Switzerland
[La] Idioma:eng; fre
[Mh] Termos MeSH primário: Erradicação de Doenças
Programas de Imunização
Poliomielite/prevenção & controle
Vacina Antipólio Oral/administração & dosagem
Poliovirus/imunologia
[Mh] Termos MeSH secundário: Seres Humanos
Lactente
Militares
Nigéria/epidemiologia
Poliomielite/epidemiologia
Poliomielite/transmissão
Segurança
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Poliovirus Vaccine, Oral)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180303
[St] Status:MEDLINE


  8 / 9069 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29384309
[Au] Autor:Boa A; Douba A; N Guessan TB; Menan H; Attia A; Ouassa T; Bénié JBV; Abokon A; Dosso M; Aholi P; Timité-Konan M; Abauleth RY; Bissagnéné E; Aka J; Yavo JC; Sylvain BJ; Ouattara GS; Ekra DK; Sow K; Kouassi JNG; Ahoussou EMK; Dally RK
[Ti] Título:[A plea for introduction of hepatitis B vaccination at birth in Côte d'Ivoire].
[Ti] Título:Plaidoyer pour l?introduction du vaccin contre l?hépatite virale B à la naissance en Côte d?Ivoire..
[So] Source:Sante Publique;29(5):751-760, 2017 Dec 05.
[Is] ISSN:0995-3914
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:The Côte d'Ivoire National Immunization Technical Advisory Group 2015 work plan included elaboration of an opinion on inclusion of hepatitis B vaccination at birth in the Expanded Program on Immunization (EPI) in Côte d'Ivoire. A task force was set up to conduct this assessment according to a systematized method. The task force analysed scientific articles on the burden of hepatitis B in Côte d'Ivoire, the burden of mother-child transmission, the impact of hepatitis B vaccination at birth in countries which have adopted this strategy, the efficacy and safety of hepatitis B vaccine in newborns, the cost-effectiveness of hepatitis B vaccination at birth, and the best strategy to introduce hepatitis B vaccination at birth in the EPI. The National Immunization Technical Advisory Group of Côte d'Ivoire finally recommended introduction of a dose of hepatitis B vaccine at birth in the context of the Expanded Program on Immunization with maintenance of three doses of pentavalent vaccine (DPT-HepB-Hib) at 6, 10, and 14 weeks of age.
[Mh] Termos MeSH primário: Comitês Consultivos
Vacinas contra Hepatite B
Programas de Imunização
[Mh] Termos MeSH secundário: Costa do Marfim
Seres Humanos
Recém-Nascido
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis B Vaccines)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.3917/spub.175.0751


  9 / 9069 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29474026
[Ti] Título:BCG vaccines: WHO position paper ­ February 2018.
[Ti] Título:Vaccins BCG: Note de synthèse de l'OMS ­ Février 2018..
[So] Source:Wkly Epidemiol Rec;93(8):73-96, 2018 Feb 23.
[Is] ISSN:0049-8114
[Cp] País de publicação:Switzerland
[La] Idioma:eng; fre
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/administração & dosagem
Vacina BCG/administração & dosagem
Guias como Assunto/normas
Programas de Imunização/normas
Organização Mundial da Saúde
[Mh] Termos MeSH secundário: Adulto
Comitês Consultivos/normas
Idoso
Úlcera de Buruli/diagnóstico
Úlcera de Buruli/epidemiologia
Úlcera de Buruli/terapia
Criança
Pré-Escolar
Feminino
Saúde Global/estatística & dados numéricos
Seres Humanos
Programas de Imunização/estatística & dados numéricos
Esquemas de Imunização
Imunização Secundária
Lactente
Hanseníase/diagnóstico
Hanseníase/epidemiologia
Hanseníase/terapia
Masculino
Meia-Idade
Gravidez
Tuberculose/diagnóstico
Tuberculose/epidemiologia
Tuberculose/terapia
Tuberculose/transmissão
Tuberculose Resistente a Múltiplos Medicamentos/epidemiologia
Tuberculose Pulmonar/diagnóstico
Tuberculose Pulmonar/epidemiologia
Tuberculose Pulmonar/terapia
Tuberculose Pulmonar/transmissão
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (BCG Vaccine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180224
[St] Status:MEDLINE


  10 / 9069 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29342498
[Au] Autor:Jacobson Vann JC; Jacobson RM; Coyne-Beasley T; Asafu-Adjei JK; Szilagyi PG
[Ad] Endereço:School of Nursing, The University of North Carolina at Chapel Hill, Carrington Hall, Chapel Hill, North Carolina, USA, 27599-7460.
[Ti] Título:Patient reminder and recall interventions to improve immunization rates.
[So] Source:Cochrane Database Syst Rev;1:CD003941, 2018 01 18.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Immunization rates for children and adults are rising, but coverage levels have not reached optimal goals. As a result, vaccine-preventable diseases still occur. In an era of increasing complexity of immunization schedules, rising expectations about the performance of primary care, and large demands on primary care providers, it is important to understand and promote interventions that work in primary care settings to increase immunization coverage. One common theme across immunization programs in many nations involves the challenge of implementing a population-based approach and identifying all eligible recipients, for example the children who should receive the measles vaccine. However, this issue is gradually being addressed through the availability of immunization registries and electronic health records. A second common theme is identifying the best strategies to promote high vaccination rates. Three types of strategies have been studied: (1) patient-oriented interventions, such as patient reminder or recall, (2) provider interventions, and (3) system interventions, such as school laws. One of the most prominent intervention strategies, and perhaps best studied, involves patient reminder or recall systems. This is an update of a previously published review. OBJECTIVES: To evaluate and compare the effectiveness of various types of patient reminder and recall interventions to improve receipt of immunizations. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase and CINAHL to January 2017. We also searched grey literature and trial registers to January 2017. SELECTION CRITERIA: We included randomized trials, controlled before and after studies, and interrupted time series evaluating immunization-focused patient reminder or recall interventions in children, adolescents, and adults who receive immunizations in any setting. We included no-intervention control groups, standard practice activities that did not include immunization patient reminder or recall, media-based activities aimed at promoting immunizations, or simple practice-based awareness campaigns. We included receipt of any immunizations as eligible outcome measures, excluding special travel immunizations. We excluded patients who were hospitalized for the duration of the study period. DATA COLLECTION AND ANALYSIS: We used the standard methodological procedures expected by Cochrane and the Cochrane Effective Practice and Organisation of Care (EPOC) Group. We present results for individual studies as relative rates using risk ratios, and risk differences for randomized trials, and as absolute changes in percentage points for controlled before-after studies. We present pooled results for randomized trials using the random-effects model. MAIN RESULTS: The 75 included studies involved child, adolescent, and adult participants in outpatient, community-based, primary care, and other settings in 10 countries.Patient reminder or recall interventions, including telephone and autodialer calls, letters, postcards, text messages, combination of mail or telephone, or a combination of patient reminder or recall with outreach, probably improve the proportion of participants who receive immunization (risk ratio (RR) of 1.28, 95% confidence interval (CI) 1.23 to 1.35; risk difference of 8%) based on moderate certainty evidence from 55 studies with 138,625 participants.Three types of single-method reminders improve receipt of immunizations based on high certainty evidence: the use of postcards (RR 1.18, 95% CI 1.08 to 1.30; eight studies; 27,734 participants), text messages (RR 1.29, 95% CI 1.15 to 1.44; six studies; 7772 participants), and autodialer (RR 1.17, 95% CI 1.03 to 1.32; five studies; 11,947 participants). Two types of single-method reminders probably improve receipt of immunizations based on moderate certainty evidence: the use of telephone calls (RR 1.75, 95% CI 1.20 to 2.54; seven studies; 9120 participants) and letters to patients (RR 1.29, 95% CI 1.21 to 1.38; 27 studies; 81,100 participants).Based on high certainty evidence, reminders improve receipt of immunizations for childhood (RR 1.22, 95% CI 1.15 to 1.29; risk difference of 8%; 23 studies; 31,099 participants) and adolescent vaccinations (RR 1.29, 95% CI 1.17 to 1.42; risk difference of 7%; 10 studies; 30,868 participants). Reminders probably improve receipt of vaccinations for childhood influenza (RR 1.51, 95% CI 1.14 to 1.99; risk difference of 22%; five studies; 9265 participants) and adult influenza (RR 1.29, 95% CI 1.17 to 1.43; risk difference of 9%; 15 studies; 59,328 participants) based on moderate certainty evidence. They may improve receipt of vaccinations for adult pneumococcus, tetanus, hepatitis B, and other non-influenza vaccinations based on low certainty evidence although the confidence interval includes no effect of these interventions (RR 2.08, 95% CI 0.91 to 4.78; four studies; 8065 participants). AUTHORS' CONCLUSIONS: Patient reminder and recall systems, in primary care settings, are likely to be effective at improving the proportion of the target population who receive immunizations.
[Mh] Termos MeSH primário: Imunização/utilização
Sistemas de Alerta
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Correspondência como Assunto
Seres Humanos
Programas de Imunização/organização & administração
Ensaios Clínicos Controlados Aleatórios como Assunto
Sistemas de Alerta/estatística & dados numéricos
Telefone/estatística & dados numéricos
Mensagem de Texto/estatística & dados numéricos
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD003941.pub3



página 1 de 907 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde